PAH in systemic sclerosis
Adapted from Hao Y, et al. 2016.4
GI, gastrointestinal; ILD, interstitial lung disease.
About 1 in 10 patients with SSc will develop PAH during their lifetime.3
PAH is a leading cause of death in SSc, and mortality in these patients remains unacceptably high.4 Patients with SSc-PAH have poorer outcomes and almost 3 times higher mortality compared to patients with PAH from other causes.1
SSc screening programs can reduce mortality5
Screening in SSc populations enables earlier diagnosis of PAH, facilitating earlier intervention and improving long-term survival.5 Annual cardiopulmonary screening is recommended in all patients with SSc, in order to identify patients who should have a right heart catheterisation to diagnose potential PAH.2